MediPharm Labs (TSE:LABS) Director Christopher David Taves Sells 176,786 Shares

MediPharm Labs Corp. (TSE:LABS) Director Christopher David Taves sold 176,786 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of C$0.08, for a total value of C$14,142.88. Following the completion of the transaction, the director owned 2,847,939 shares of the company’s stock, valued at approximately C$227,835.12. This represents a 5.84% decrease in their position.

MediPharm Labs Price Performance

Shares of LABS remained flat at C$0.07 during trading on Friday. The company’s stock had a trading volume of 75,364 shares, compared to its average volume of 237,688. The business’s fifty day moving average price is C$0.07 and its two-hundred day moving average price is C$0.07. MediPharm Labs Corp. has a one year low of C$0.06 and a one year high of C$0.10. The company has a market cap of C$29.74 million, a P/E ratio of -3.50 and a beta of -0.61. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.10 and a current ratio of 3.02.

About MediPharm Labs

Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products produced in a GMP-certified facility with ISO-standard clean rooms. MediPharm has invested in an expert research-driven team, state-of-the-art technology, advanced purification methodologies, and purpose-built facilities to deliver pure, trusted, precision-dosed cannabinoid products for domestic and international markets.